PTC Therapeutics Exceeds 2025 Revenue Guidance, Projects Strong 2026 Growth, Advances HD Program
PTCT has more than doubled off its 52-week low of $35.95.
Summary
PTC Therapeutics reported preliminary 2025 revenues that exceeded guidance and provided 2026 product revenue guidance indicating significant year-over-year growth, alongside positive updates for its Huntington's disease program.
Key Events · Earnings and Guidance · PTCT
-
Exceeded 2025 Revenue Guidance
Reported preliminary total unaudited net product and royalty revenue of approximately $823.4 million for fiscal year 2025, surpassing previous guidance.
-
Strong 2026 Revenue Guidance
Anticipates full-year 2026 total product revenues of $700 million to $800 million, excluding Evrysdi royalty and collaboration revenue, representing 19-36% year-over-year growth.
-
Sephience Launch Momentum
Sephience generated approximately $112.1 million in net revenue since launch in 2025, with strong Q4 performance of $92.5 million and 946 patients on commercial therapy worldwide.
-
Advancement in Huntington's Disease Program
Reached alignment with the FDA on the design of a global Phase 3 trial for votoplam, planned for H1 2026, with the FDA open to an Accelerated Approval pathway.
Analysis · PTCT · Life Sciences
PTC Therapeutics delivered a strong financial update, with preliminary 2025 results exceeding expectations and robust revenue growth projected for 2026. The successful launch of Sephience and the significant progress in the votoplam Huntington's disease program, including FDA alignment on a Phase 3 trial and openness to accelerated approval, are key drivers for future value. The company's substantial cash reserves provide a solid foundation for continued R&D and commercialization efforts. Investors should monitor the Sephience global rollout and the initiation of the votoplam Phase 3 trial.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PTCT was trading at $76.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $35.95 to $87.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.